Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lithium Augmentation of Ketamine for Treatment-Resistant Depression
NCT03290963Phase 2Withdrawn
- Start
- Nov 2017
- Primary completion
- Dec 2018
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lithium in treatment-resistant depression (TRD). Primary endpoint: Montgomery-Asberg Depression Rating Scale at 1 day. Planned start Nov 2017; status: withdrawn.
02
Drugs
lithium
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT03290963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03290963.